NYSE$EHC

Encompass Health Corp · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Encompass Health's Q1 2023 performance was driven by strong discharge growth and improved labor costs.

Encompass Health reported a strong first quarter in 2023, with a 9.5% increase in net operating revenue and a 17.5% growth in Adjusted EBITDA. The company's performance was driven by a 9.4% increase in discharges and substantial improvement in labor costs. Encompass Health also increased its full-year guidance for net operating revenue, Adjusted EBITDA, and adjusted earnings per share.

  • Revenue growth of 9.5% was primarily driven by increased volumes, with total discharge growth of 9.4% including same-store growth of 5.9%.
  • Cash flows provided by operating activities increased 4.1% year-over-year to $227.9 million, primarily due to improved collections of accounts receivable.
  • Adjusted EBITDA increased by 17.5%, primarily due to increased revenue and a decrease in contract labor expense and sign-on and shift bonuses.
  • The company increased its full-year guidance for net operating revenue to $4,700 to $4,770 million and for adjusted earnings per share from continuing operations attributable to Encompass Health to $2.94 to $3.23.

Headline financials

Total Revenue

$1.16B

Previous: $1.33B-13.0%
EPS (adj)

$0.88

Previous: $0.97-9.3%
Discharges

55.6K

Previous: 50.8K+9.4%
Net patient revenue per discharge

$20.4K

Previous: $20.4K+0.0%
Capital Expenditures

-$96.6M

Previous: -$115M+16.1%
Free Cash Flow

-$8.9M

Previous: -$27.7M+67.9%
Net Income

$87.7M

Previous: $87.5M+0.2%
Operating Income

-$221M

Previous: -$231M+4.0%
Gross Profit

$1.11B

Previous: $1.28B-13.4%
Cash & Equivalents

$85M

Previous: $94.2M-9.8%
Total Assets

$5.75B

Previous: $6.94B-17.2%
Stock-Based Comp

$7.9M

Previous: $6.1M+29.5%

Revenue & EPS history

Encompass Health · Revenue · Quarterly

$1.16B

Q1 2023-13%vs Q1 2022
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

The Company increased its full-year guidance as follows:

Tailwinds

  • Net operating revenue is now expected to be between $4,700 million and $4,770 million.
  • Adjusted EBITDA is projected to be in the range of $870 million to $910 million.
  • Adjusted earnings per share from continuing operations attributable to Encompass Health are anticipated to be between $2.94 and $3.23.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+1.2%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+2.5%

Avg return

30 days after

64%

42 / 66 earnings

Positive

+11.8%

Q1 2025

Best reaction

-9.0%

Q1 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.1%+5.0%+6.0%
Q4 2025+5.9%+13.9%+7.4%
Q3 2025-6.9%-6.8%-7.5%
Q1 2025+11.8%+15.4%+17.2%
Q4 2024+1.3%-0.6%+0.7%
Q3 2024+7.0%+5.8%+10.0%
Q2 2024-8.7%-7.5%+1.0%
Q1 2024+0.3%+1.4%+2.5%
Q4 2023+1.7%+1.9%+5.9%
Q3 2023-1.9%+0.9%+6.7%
Q2 2023+5.0%+6.4%+7.6%
Q1 2023+0.7%-0.6%-5.9%
Q4 2022+1.6%+3.1%-9.1%
Q3 2022+6.4%+11.1%+16.6%
Q2 2022+0.6%+4.5%-4.0%
Q1 2022+2.6%+2.5%-2.0%
Q4 2021+1.5%-2.9%+8.8%
Q3 2021-6.0%-5.8%-9.8%
Q2 2021+0.7%+3.5%-4.1%
Q1 2021-1.6%-2.7%-2.5%
Q4 2020-3.9%-6.2%-6.1%
Q3 2020-2.6%-3.0%+25.9%
Q2 2020+4.5%+3.1%-6.4%
Q1 2020-1.1%-7.1%+6.4%
Q4 2019+0.4%+3.1%-2.6%
Q3 2019-5.8%+2.0%+5.5%
Q2 2019-4.0%-7.4%-12.6%
Q1 2019+5.3%+3.6%-4.6%
Q4 2018-4.4%-3.5%-13.3%
Q3 2018-5.7%-4.0%+1.4%
Q2 2018+8.8%+5.9%+17.4%
Q1 2018+7.2%+7.3%+10.3%
Q4 2017+3.0%+3.9%+7.7%
Q3 2017+1.8%+2.0%+8.7%
Q2 2017+1.9%-0.2%+3.6%
Q1 2017+7.9%+10.0%+6.3%
Q4 2016+0.1%+0.5%-1.9%
Q3 2016+1.8%+0.7%+5.6%
Q2 2016+6.7%+3.1%-0.3%
Q1 2016+10.9%
Q4 2015+9.2%
Q3 2015-0.3%
Q2 2015-2.9%
Q1 2015-9.0%
Q4 2014-4.7%
Q3 2014-3.0%
Q2 2014+7.4%
Q1 2014-0.4%
Q4 2013-2.8%
Q3 2013+0.6%
Q2 2013+4.7%
Q1 2013+3.1%
Q4 2012+7.2%
Q3 2012+2.5%
Q2 2012-3.7%
Q1 2012+9.2%
Q4 2010+3.9%
Q4 2011+3.9%
Q3 2011-1.0%
Q2 2011-9.0%
Q1 2010+0.4%
Q1 2011+2.5%
Q4 2008+7.8%
Q3 2010+2.2%
Q2 2010-1.0%
Q4 2009-1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro